 NEW YORK, Feb. 22, 2021 GLOBE NEWSWIRE -- Renalytix AI plc LSE: RENX NASDAQ: RNLX RenalytixAI or the Company, the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it will report its financial results for the six and three months ended December 31, 2020 on Tuesday, March 2, 2021. 